India has said that its trade talks with the US helped place it in a lower tier of additional tariffs imposed by the Trump administration, securing an advantage for key export categories over regional competitors. Government officials confirmed that 45% of India’s total $87.3 billion in exports to the US, including generic pharmaceuticals and smartphones, remain exempt from the new 10% Section 301 levy that took effect last week.
The clarification comes as the US rolled out Section 301 tariffs of 10-12.5% on 60 trading partners from July 24, 2026, replacing the temporary Section 122 duties. Indian officials say the exemptions carved out for pharmaceuticals and electronics reflect the outcome of sustained bilateral trade negotiations over the preceding months.
How Does the Tariff Exemption Benefit Indian Exporters?
The exemption for generic pharmaceuticals is significant given India’s position as a leading global supplier of generic drugs to the US market, while the smartphone exemption protects a fast-growing electronics manufacturing and export base built up under production-linked incentive schemes. With 45% of India’s $87.3 billion in US-bound exports shielded from the new levy, exporters in these categories retain a cost advantage over competitors in countries facing the full 10-12.5% Section 301 rate.
What Do Trade Officials and Economists Say?
The Economic Advisory Council to the Prime Minister has said the broader India-US trade arrangement, which brings down the reciprocal tariff on Indian goods to 18%, lower than rates facing China, Bangladesh, and Vietnam, is expected to boost foreign direct investment and portfolio inflows. EAC-PM chairman commentary noted the deal should have a positive impact on the rupee as FDI and FII flows, previously affected by tariff uncertainty, are expected to strengthen.
Market and Trade Reaction
The rupee and Indian equities have shown resilience following the trade clarity, with the Sensex and Nifty posting gains in recent sessions partly attributed to reduced tariff-related uncertainty. Pharmaceutical and electronics manufacturing stocks have drawn investor interest as analysts price in continued export competitiveness. The development follows India’s recent conclusion of free trade agreements with the UK and EFTA nations, reinforcing a broader diversification of India’s export markets beyond the US.
What Happens Next?
India’s trade negotiators are expected to continue engagement with the US Trade Representative’s office to expand exemption categories and push for a further reduction in the 18% reciprocal tariff rate. Exporters in non-exempt sectors will be watching for signs of additional bilateral carve-outs as the 60-country Section 301 tariff regime beds in over the coming months.
Frequently Asked Questions
What tariff advantage did India secure in US trade talks?
India secured exemptions for generic pharmaceuticals and smartphones from the new 10% Section 301 levy, covering 45% of its $87.3 billion in exports to the US, while its overall reciprocal tariff was set at 18%, lower than China, Bangladesh, and Vietnam.
How will the trade deal affect the rupee and FDI?
According to the EAC-PM chairman, the India-US trade arrangement is expected to boost FDI and FII inflows and have a positive impact on the rupee by reducing tariff-related uncertainty for investors.
Which Indian export sectors benefit most from the exemptions?
Generic pharmaceutical manufacturers and smartphone exporters benefit most, as these categories are exempt from the new Section 301 tariff that applies to most other Indian goods entering the US.
Leave a comment